Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
Tombal B, Saad F, Penson D, Hussain M, Sternberg CN, Morlock R, Ramaswamy K, Ivanescu C, Attard G. Tombal B, et al. Among authors: morlock r. Lancet Oncol. 2019 Apr;20(4):556-569. doi: 10.1016/S1470-2045(18)30898-2. Epub 2019 Feb 12. Lancet Oncol. 2019. PMID: 30770294 Clinical Trial.
Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study.
Stenzl A, Dunshee C, De Giorgi U, Alekseev B, Iguchi T, Szmulewitz RZ, Flaig TW, Tombal B, Morlock R, Ivanescu C, Ramaswamy K, Saad F, Armstrong AJ. Stenzl A, et al. Among authors: morlock r. Eur Urol. 2020 Oct;78(4):603-614. doi: 10.1016/j.eururo.2020.03.019. Epub 2020 Apr 23. Eur Urol. 2020. PMID: 32336645 Free article. Clinical Trial.
Targeted literature review of the global burden of gastric cancer.
Casamayor M, Morlock R, Maeda H, Ajani J. Casamayor M, et al. Among authors: morlock r. Ecancermedicalscience. 2018 Nov 26;12:883. doi: 10.3332/ecancer.2018.883. eCollection 2018. Ecancermedicalscience. 2018. PMID: 30679950 Free PMC article. Review.
Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma.
Lordick F, Al-Batran SE, Ganguli A, Morlock R, Sahin U, Türeci Ö. Lordick F, et al. Among authors: morlock r. Gastric Cancer. 2021 May;24(3):721-730. doi: 10.1007/s10120-020-01153-6. Epub 2021 Mar 23. Gastric Cancer. 2021. PMID: 33755863 Free PMC article. Clinical Trial.
62 results